Poland· PL-100466998
Tepmetko
A tepotinib product containing tepotinibum, registered in Poland by Merck Europe B.V.. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tepotinib is registered in 3 of 19 countries.
Countries holding a registration under ATC L01EX21 (tepotinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 1 of them publish a price we can compare per daily dose
Tepotinib · ATC L01EX21
3 / 19 countries
- Canada
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Tepotinibum
- Manufacturer
- Merck Europe B.V.
- Country
- Poland (PL)
- ATC code
- L01EX21
- ATC class
- Tepotinib
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin04065267923918
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tepotinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTEPMETKOAbacus Medicine A/S
- SwitzerlandTepmetko 225 mg, FilmtablettenMerck (Schweiz) AG
- CzechiaTEPMETKOMerck Europe B.V., Amsterdam
- SpainTEPMETKO 225 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Europe B.V.
- IrelandTEPMETKO 225 mg film-coated tabletsMerck Europe B.V.
- IcelandTEPMETKOMerck Europe B.V.*
- NetherlandsTepmetko 225 mg, filmomhulde tablettenMerck Europe B.V.
- NorwayTepmetkoMerck Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tepmetko
- Liechtenstein · Tepmetko
- Norway · Tepmetko
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/abd67bfd-17f4-4cbe-97b0-33aa87bbb658 GET /v1/drugs/abd67bfd-17f4-4cbe-97b0-33aa87bbb658?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "225 mg",
"packaging": "Rpz ¦ EU/1/21/1596/001 ¦ 144739\n60 tabl.\n¦ UR/Z/4c/187/24 ¦ UR/Z/4c/047/24 - 04065267923918 ¦ UR/Z/4c/037/24 - 04065267923918 ¦ UR/Z/4c/085/22 - 04065267923918 ¦ UR/Z/4c/060/24 - 04065267923918 ¦ UR/Z/4c/232/26 - 04065267923918",
"substance": "Tepotinibum 225 mg",
"common_name": "Tepotinibum",
"pl_product_id": "100466998",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tepotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.